223 related articles for article (PubMed ID: 35697573)
1. Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
Shanmugaraj B; Khorattanakulchai N; Panapitakkul C; Malla A; Im-Erbsin R; Inthawong M; Sunyakumthorn P; Hunsawong T; Klungthong C; Reed MC; Kemthong T; Suttisan N; Malaivijitnond S; Srimangkornkaew P; Klinkhamhom A; Manopwisedjaroen S; Thitithanyanont A; Taychakhoonavudh S; Phoolcharoen W
Vaccine; 2022 Jul; 40(32):4440-4452. PubMed ID: 35697573
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.
Phoolcharoen W; Shanmugaraj B; Khorattanakulchai N; Sunyakumthorn P; Pichyangkul S; Taepavarapruk P; Praserthsee W; Malaivijitnond S; Manopwisedjaroen S; Thitithanyanont A; Srisutthisamphan K; Jongkaewwattana A; Tomai M; Fox CB; Taychakhoonavudh S
Vaccine; 2023 Apr; 41(17):2781-2792. PubMed ID: 36963999
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity and efficacy of Relcovax®, a dual receptor binding domain (RBD) and nucleocapsid (N) subunit protein vaccine candidate against SARS-CoV-2 virus.
Sathe N; Shaikh S; Bhavsar M; Parte L; Gadiparthi A; Kad S; Sensarma S; Nalband H; Sangapillai R; Sivashanmuganathan S; Pusalkar R; Anandan S; Masand G; Pratapreddy K; Harinarayana Rao S; Gokhale A; Vidyadhar Reddy GEC; Karanam G; Phatarphekar A; Rao P; Ramana V; Ramnath RL
Vaccine; 2024 Feb; 42(5):1051-1064. PubMed ID: 37816655
[TBL] [Abstract][Full Text] [Related]
4. Receptor binding domain proteins of SARS-CoV-2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern.
Khorattanakulchai N; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Srisutthisamphan K; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Shanmugaraj B; Phoolcharoen W
J Med Virol; 2022 Sep; 94(9):4265-4276. PubMed ID: 35615895
[TBL] [Abstract][Full Text] [Related]
5. A novel RBD-protein/peptide vaccine elicits broadly neutralizing antibodies and protects mice and macaques against SARS-CoV-2.
Wang S; Wang CY; Kuo HK; Peng WJ; Huang JH; Kuo BS; Lin F; Liu YJ; Liu Z; Wu HT; Ding S; Hou KL; Cheng J; Yang YT; Jiang MH; Wang MS; Chen T; Xia WG; Lin E; Hung CH; Chen HJ; Shih Z; Lin YL; Ryan V; Hu MM; Heppner DG; Malherbe DC; Periasamy S; Kuzmina N; Subramani C; Hellerstein M; Monath TP; Rumyantsev A; Bukreyev A; Guirakhoo F
Emerg Microbes Infect; 2022 Dec; 11(1):2724-2734. PubMed ID: 36287714
[TBL] [Abstract][Full Text] [Related]
6. A recombinant subunit vaccine candidate produced in plants elicits neutralizing antibodies against SARS-CoV-2 variants in macaques.
Khorattanakulchai N; Srisutthisamphan K; Shanmugaraj B; Manopwisedjaroen S; Rattanapisit K; Panapitakkul C; Kemthong T; Suttisan N; Malaivijitnond S; Thitithanyanont A; Jongkaewwattana A; Phoolcharoen W
Front Plant Sci; 2022; 13():901978. PubMed ID: 36247553
[TBL] [Abstract][Full Text] [Related]
7. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and efficacy of recombinant subunit SARS-CoV-2 vaccine candidate in the Syrian hamster model.
Shanmugaraj B; Khorattanakulchai N; Paungpin W; Akkhawattanangkul Y; Manopwisedjaroen S; Thitithanyanont A; Phoolcharoen W
Biotechnol Rep (Amst); 2023 Mar; 37():e00779. PubMed ID: 36533163
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
10. Development of an IgG-Fc fusion COVID-19 subunit vaccine, AKS-452.
Alleva DG; Delpero AR; Scully MM; Murikipudi S; Ragupathy R; Greaves EK; Sathiyaseelan T; Haworth JR; Shah NJ; Rao V; Nagre S; Lancaster TM; Webb SS; Jasa AI; Ronca SE; Green FM; Elyard HA; Yee J; Klein J; Karnes L; Sollie F; Zion TC
Vaccine; 2021 Oct; 39(45):6601-6613. PubMed ID: 34642088
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
[TBL] [Abstract][Full Text] [Related]
12. Elicitation of potent neutralizing antibodies in obese mice by ISA 51-adjuvanted SARS-CoV-2 spike RBD-Fc vaccine.
Li CJ; Jiang CL; Chao TL; Lin SY; Tsai YM; Chao CS; Su YT; Chen CJ; Chang SY; Lin FJ; Chang SC
Appl Microbiol Biotechnol; 2023 May; 107(9):2983-2995. PubMed ID: 36988669
[TBL] [Abstract][Full Text] [Related]
13. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
14. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models.
Conforti A; Marra E; Palombo F; Roscilli G; Ravà M; Fumagalli V; Muzi A; Maffei M; Luberto L; Lione L; Salvatori E; Compagnone M; Pinto E; Pavoni E; Bucci F; Vitagliano G; Stoppoloni D; Pacello ML; Cappelletti M; Ferrara FF; D'Acunto E; Chiarini V; Arriga R; Nyska A; Di Lucia P; Marotta D; Bono E; Giustini L; Sala E; Perucchini C; Paterson J; Ryan KA; Challis AR; Matusali G; Colavita F; Caselli G; Criscuolo E; Clementi N; Mancini N; Groß R; Seidel A; Wettstein L; Münch J; Donnici L; Conti M; De Francesco R; Kuka M; Ciliberto G; Castilletti C; Capobianchi MR; Ippolito G; Guidotti LG; Rovati L; Iannacone M; Aurisicchio L
Mol Ther; 2022 Jan; 30(1):311-326. PubMed ID: 34547465
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19.
Tran TNM; May BP; Ung TT; Nguyen MK; Nguyen TTT; Dinh VL; Doan CC; Tran TV; Khong H; Nguyen TTT; Hua HQH; Nguyen VA; Ha TP; Phan DL; Nguyen TA; Bui TN; Tu TM; Nguyen TT; Le TTH; Dong TL; Huynh TH; Ho PH; Le NTT; Truong CT; Pham HP; Luong CY; Y NL; Cao MN; Nguyen DK; Le TT; Vuong DC; Nguyen LKH; Do MS
Front Immunol; 2021; 12():766112. PubMed ID: 34938290
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
Hashimoto M; Nagata N; Homma T; Maeda H; Dohi K; Seki NM; Yoshihara K; Iwata-Yoshikawa N; Shiwa-Sudo N; Sakai Y; Shirakura M; Kishida N; Arita T; Suzuki Y; Watanabe S; Asanuma H; Sonoyama T; Suzuki T; Omoto S; Hasegawa H
Vaccine; 2022 Jul; 40(31):4231-4241. PubMed ID: 35691872
[TBL] [Abstract][Full Text] [Related]
17. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase I/II safety and immunogenicity study of the Montanide-adjuvanted SARS-CoV-2 spike protein-RBD-Fc vaccine, AKS-452.
Feitsma EA; Janssen YF; Boersma HH; van Sleen Y; van Baarle D; Alleva DG; Lancaster TM; Sathiyaseelan T; Murikipudi S; Delpero AR; Scully MM; Ragupathy R; Kotha S; Haworth JR; Shah NJ; Rao V; Nagre S; Ronca SE; Green FM; Aminetzah A; Sollie F; Kruijff S; Brom M; van Dam GM; Zion TC
Vaccine; 2023 Mar; 41(13):2184-2197. PubMed ID: 36842886
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
Banihashemi SR; Es-Haghi A; Fallah Mehrabadi MH; Nofeli M; Mokarram AR; Ranjbar A; Salman M; Hajimoradi M; Razaz SH; Taghdiri M; Bagheri M; Dadar M; Hassan ZM; Eslampanah M; Salehi Najafabadi Z; Lotfi M; Khorasani A; Rahmani F
Front Immunol; 2022; 13():836745. PubMed ID: 35693788
[TBL] [Abstract][Full Text] [Related]
20. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
